NCT02157506 - A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

July 31, 2015

Conditions

Heart FailureDecompensated Heart FailureAcute Heart Failure

Interventions

DRUG

CXL-1427

DRUG

Placebo

Trial Locations (35)

2105

Cardioxyl Study Site, Kiel

11193

Cardioxyl Study Site, Amman

12134

Cardioxyl Study Site, Moscow

17475

Cardioxyl Study Site, Greifswald

19242

Cardioxyl Study Site, Saint Petersburg

21201

Cardioxyl Study Site, Baltimore

22110

Cardioxyl Study Site, Irbid

23298

Cardioxyl Study Site, Richmond

27517

Cardioxyl Study Site, Chapel Hill

29425

Cardioxyl Study Site, Charleston

31201

Cardioxyl Study Site, Macon

32209

Cardioxyl Study Site, Jacksonville

32224

Cardioxyl Study Site, Jacksonville

32610

Cardioxyl Study Site, Gainesville

37075

Cardioxyl Study Site, Göttingen

37232

Cardioxyl Study Site, Nashville

43201

Cardioxyl Study Site, Columbus

45267

Cardioxyl Study Site, Cincinnati

48202

Cardioxyl Study Site, Detroit

50937

Cardioxyl Study Site, Cologne

50981

Cardioxyl Study Site, Wroclaw

60590

Cardioxyl Study Site, Frankfurt

61231

Cardioxyl Study Site, Bad Neuheim

84132

Cardioxyl Study Site, Salt Lake City

93053

Cardioxyl Study Site, Regensberg

93487

Cardioxyl Study Site, Lodz

111539

Cardioxyl Study Site, Moscow

121309

Cardioxyl Study Site, Moscow

127644

Cardioxyl Study Site, Moscow

199106

Cardioxyl Study Site, Saint Petersburg

634012

Cardioxyl Study Site, Tomsk

650002

Cardioxyl Study Site, Kemerovo

07103

Cardioxyl Study Site, Newark

01211

Cardioxyl Study SIte, Warsaw

04-628

Cardioxyl Study Site, Warsaw